Background: The impact of calcineurin inhibitors on achievement of sustained virological response to antiviral therapy for post-transplant recurrent hepatitis C is controversial. This study aimed at investigating the interactions between calcineurin inhibitors and interleukin-28B (IL-28B) gene polymorphisms and sustained virological response. Methods: Retrospective study of 147 liver transplant recipients with recurrent hepatitis C, who received 48 weeks of peg-interferon-α (N=113) or standard interferon (N=34), in association with ribavirin. Cyclosporine and tacrolimus were administered in 68 and 79 patients, respectively. IL-28B rs12979860 allele frequency was assessed in both donors and recipients. Results: Overall, 57 patients (38.8%) obtained sustained virological response; no difference was found between cyclosporine and tacrolimus-treated patients (42.6% vs. 35.4%, p=0.371). Recipient and donor IL-28B genotypic frequencies were C/C=30.6%, C/T=51.7%, T/T=17.7% and C/C=44.9%, C/T=50.3%, T/T=4.8%, respectively. Combining donor and recipient alleles, response rates decreased from cyclosporine-treated patients carrying ≤1 T allele (56.1%) to tacrolimus-treated patients carrying ≤1 T allele (44.7%) to patients carrying ≥2 T alleles (25.0%, p=0.0009). Conclusions: Donor and recipient rs12979860 alleles synergistically influence sustained virological response rate to antiviral treatment for recurrent hepatitis C. In patients carrying <2 T alleles cyclosporine favours a better response than tacrolimus, while no difference was found in the presence of ≥2 T alleles.

Bitetto, D., De Feo, T., Mantovani, M., Falleti, E., Fabris, C., Belli, L., et al. (2013). Interaction between calcineurin inhibitors and IL-28B rs12979860 C>T polymorphism and response to treatment for post-transplant recurrent hepatitis C. DIGESTIVE AND LIVER DISEASE, 45(11), 927-932 [10.1016/j.dld.2013.04.006].

Interaction between calcineurin inhibitors and IL-28B rs12979860 C>T polymorphism and response to treatment for post-transplant recurrent hepatitis C

Fagiuoli S;
2013

Abstract

Background: The impact of calcineurin inhibitors on achievement of sustained virological response to antiviral therapy for post-transplant recurrent hepatitis C is controversial. This study aimed at investigating the interactions between calcineurin inhibitors and interleukin-28B (IL-28B) gene polymorphisms and sustained virological response. Methods: Retrospective study of 147 liver transplant recipients with recurrent hepatitis C, who received 48 weeks of peg-interferon-α (N=113) or standard interferon (N=34), in association with ribavirin. Cyclosporine and tacrolimus were administered in 68 and 79 patients, respectively. IL-28B rs12979860 allele frequency was assessed in both donors and recipients. Results: Overall, 57 patients (38.8%) obtained sustained virological response; no difference was found between cyclosporine and tacrolimus-treated patients (42.6% vs. 35.4%, p=0.371). Recipient and donor IL-28B genotypic frequencies were C/C=30.6%, C/T=51.7%, T/T=17.7% and C/C=44.9%, C/T=50.3%, T/T=4.8%, respectively. Combining donor and recipient alleles, response rates decreased from cyclosporine-treated patients carrying ≤1 T allele (56.1%) to tacrolimus-treated patients carrying ≤1 T allele (44.7%) to patients carrying ≥2 T alleles (25.0%, p=0.0009). Conclusions: Donor and recipient rs12979860 alleles synergistically influence sustained virological response rate to antiviral treatment for recurrent hepatitis C. In patients carrying <2 T alleles cyclosporine favours a better response than tacrolimus, while no difference was found in the presence of ≥2 T alleles.
Articolo in rivista - Articolo scientifico
Antiviral therapy; Calcineurin inhibitors; Chronic hepatitis; Interleukin-28B polymorphisms; Liver transplantation;
English
927
932
6
Bitetto, D., De Feo, T., Mantovani, M., Falleti, E., Fabris, C., Belli, L., et al. (2013). Interaction between calcineurin inhibitors and IL-28B rs12979860 C>T polymorphism and response to treatment for post-transplant recurrent hepatitis C. DIGESTIVE AND LIVER DISEASE, 45(11), 927-932 [10.1016/j.dld.2013.04.006].
Bitetto, D; De Feo, T; Mantovani, M; Falleti, E; Fabris, C; Belli, L; Fagiuoli, S; Burra, P; Piccolo, G; Donato, M; Toniutto, P; Cmet, S; Cussigh, A; Viganò, R; Airoldi, A; Pasulo, L; Colpanij, M; De Martin, E; Gambato, M; Rigamonti, C
File in questo prodotto:
File Dimensione Formato  
DLD_IL28B2013.pdf

Solo gestori archivio

Dimensione 699.6 kB
Formato Adobe PDF
699.6 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/353507
Citazioni
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
Social impact